A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: A medical research council trial

British Journal of Cancer

Volumn 93, Issue 2, 2005, Pages 178-184

  Mead, G M ^a   Cullen, M H ^b   Huddart, R ^c   Harper, P ^d   Rustin, G J S ^e   Cook, P A ^f   Stenning, S P ^f   Mason, M ^g  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d GUY S HOSPITAL   (United Kingdom)

^e MOUNT VERNON HOSPITAL   (United Kingdom)

^f MRC CLINICAL TRIALS UNIT   (United Kingdom)

^g VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

Cisplatin; Ifosfamide; Metastatic germ cell cancer; Paclitaxel; Salvage chemotherapy

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; GROWTH FACTOR; IFOSFAMIDE; PACLITAXEL;

ADULT; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG FATALITY; FEVER; GERM CELL TUMOR; GRANULOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPTICEMIA; THROMBOCYTOPENIA; TREATMENT FAILURE; TUMOR BIOPSY; TUMOR LOCALIZATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; SALVAGE THERAPY; TAXOIDS; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 23644441443     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602682     Document Type: Article

References (33)

1. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH (1995) Late relapse of testicular cancer. J Clin Oncol 13: 1170-1176
2. Beyer J, Kingreen D, Krause M, Schleicher J, Schwaner I, Schwella N, Huhn D, Siegert W (1997) Long term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy. Cancer 79: 161-168
3. Beyer J, Stenning S, Gerl A, Fossa S, Siegert W (2002) High dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann Oncol 13: 599-605
4. Bhatia S, Abonour R, Porcu P, Seshadri R, Nichols CR, Cornetta K, Einhorn LH (2000) High dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 18: 3346-3351
5. Bokemeyer C, Bayer J, Metzner B, Ruther U, Harstrick A, Weissbach L, Kohrmann U, Verbeek W, Schmoll HJ (1996) Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7: 31-34
6. Bokemeyer C, Gerl A, Schoffski P, Harstrick A, Niederle N, Beyer J, Casper J, Schmoll HJ, Kanz L (1999) Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 17: 12-516
7. de Wit R, Roberts T, Wilkinson PM, De Mulder P, Mead GM, Fossa SD, Cook P, de Prijk L, Stenning S, Collette L (2001) Equivalence of three or four cycles of bleomycin, etoposide and cisplatin chemotherapy and of a 3- or 5-day schedule in good prognosis germ cell cancer: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Co-operative Group and the Medical Research Council. J Clin Oncol 19: 1629-1640
8. Donadio AC, Sheinfeld J, Bacik J, Mazumdar M, Marion S, Bajorin DF, Bosl GJ, Motzer RJ (2003) Paclitaxel, ifosfamide and cisplatin (TIP): an effective second-line therapy for patients with relapsed testicular germ cell tumours. Proc ASCO (Abstr) 22: 1537
9. Einhorn LH, Stender MJ, Williams D (1999) Phase II trial of gemcitabine in refractory germ cell tumours. J Clin Oncol 17: 509-511
10. Farhat F, Culine S, Theodore C, Bekradda M, TerrierLacombe MJ, Droz JP (1996) Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients. Cancer 77: 1193-1197
11. Fossa SD, Stenning SP, Gerl A, Horwich A, Clark P, Wilkinson P, Jones W (1999) Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 80: 1392-1399
12. Gerl A, Clemm C, Schmeller N, Hartenstein R, Lamerz R, Wilmanns W (1995) Prognosis after salvage treatment for unselected male patients with germ cell tumours. Br J Cancer 72: 1026-1032
13. Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W (1997) Late relapse of germ cell tumours after cisplatin-based chemotherapy. Ann Oncol 8: 41-47
14. Hinton S, Catalano PJ, Einhorn LH, Nichols CR, Crawford ED, Vogelzang N, Trump D, Loehrer PJ (2002) Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Co-operative Oncology Group. J Clin Oncol 20: 1859-1863
15. Kollmannsberger C, Beyer J, Liersch R, Schoeffski P, Metzner B, Rick O, Hartmann JT, Stengele K, Hohloch K, Spott C, Kanz L, Bokemeyer C (2004) Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: A study of the German Testicular Cancer Study Group. J Clin Oncol 22: 108-114
16. Kollmannsberger C, Rick O, Derigs HG, Schleucher N, Schoffski P, Beyer J, Schoch R, Sayer HG, Gerl A, Kuczyk M, Spott C, Kanz L, Bokemeyer C (2002a) Activity of oxaliplatin in patients with relapsed or cisplatin refractory germ cell cancer: A study of the German Testicular cancer Study Group. J Clin Oncol 20: 2031-2037
17. Kollmannsberger C, Rick O, Klaproth H, Kubin T, Sayer HG, Hentrich M, Welslau M, Mayer F, Kuczyk M, Spott C, Kanz L, Bokemeyer C (2002b) Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German testicular Cancer Study Group. Br J Cancer 87: 729-732
18. Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH (1998) Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumour. J Clin Oncol 16: 2500-2504
19. Madani AA, George DW, Brames JM, Einhorn L (2003) Phase II study of epirubicin plus cisplatin in refractory germ cell tumors. Proc ASCO (Abstr) 22: 388
20. McCaffrey JA, Mazumdar M, Bajorin D, Bosl GJ, Vlamis V, Motzer RJ (1997) Ifosfamide and cisplatin chemotherapy as first line salvage therapy in germ cell tumors: response and survival. J Clin Oncol 15: 2559-2563
21. Miki T, Mizutani Y, Nonomura N, Nomoto T, Nakao M, Saiki S, Kotake T, Okuyama A (2002) Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors. Cancer 95: 1879-1885
22. Miller KD, Loehrer PJ, Gonin R, Einhorn LH (1997) Salvage chemotherapy with vinblastine, ifosfamide and cisplatin in recurrent seminoma. J Clin Oncol 15: 1427-1431
23. Motzer R, Bajorin D, Schwartz L, Hutter H, Bosl G, Scher H, Lyn P, Fischer P, Motzer RJ, Bajorin DF, Schwartz LH (1994) Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 12: 2277-2283
24. Motzer R, Gulati S, Crown J, Weisen S, Doherty M, Herr H, Fair W, Sheinfeld J, Sogani P, Russo P, Bosl G (1992) High dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Cancer 69: 550-556
25. Motzer RJ, Geller NL, Tan CC-Y, Herr H, Morse M, Fair W, Sheinfeld J, Sogani P, Russo P, Bosl G (1991) Salvage chemotherapy for patients with germ cell tumours. The Memorial Sloan-Kettering Cancer center experience (1979-1989). Cancer 67: 1305-1310
26. Motzer RJ, Mazumdar M, Sheinfeld J, Bajorin DF, Macapinlac HA, Bains M, Reich L, Flombaum C, Mariani T, Tong WP, Bosl GJ (2000a) Sequential dose intensive paclitaxel, ifosfamide, carboplatin and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 18: 1173-1180
27. Motzer RJ, Sheinfeld J, Mazumdar M, Bains M, Mariani T, Bacik J, Bajorin D, Bosl GJ (2000b) Paclitaxel, ifosfamide and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 18: 2413-2418
28. Pizzocaro G, Salvioni R, Piva L, Faustini M, Nicolai N, Gianni L (1992) Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors. Long term results. Ann Oncol 3: 211-216
29. Pont J, Bokemeyer C, Harstrick A, Sellner F, Greinix H, Stoiber F (1997) Chemotherapy for germ cell tumors relapsing after high-dose chemotherapy and stem cell support: A retrospective multicenter study of the Austrian Study Group on Urologic Oncology. Ann Oncol 8: 1229-1234
30. Porcu P, Bhatia S, Sharma M, Einhorn LH (2000) Results of treatment after relapse from high-dose chemotherapy in germ cell tumors. J Clin Oncol 18: 1181-1186
31. Rick O, Bokemeyer C, Beyer J, Hartmann JT, Schwella N, Kingreen D, Neureither S, Metzner B, Casper J, Wandt H, Hartmann F, Schmoll HJ, Derigs G, Gerl A, Berdel WE, Kanz L, Siegert W (2001) Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 19: 81-88
32. Rosti G, Pico J, Wandt H, Koza V, Salvioni R, Theodore C, Lelli G (2002) High dose chemotherapy (HDC) in the salvage treatment of patients failing first-line platinum chemotherapy in advanced germ cell tumours (GCT); first results of a prospective randomised trial of the European group for blood and marrow transplantation (EBMT): IT-94 study. Proc ASCO (Abstr) 21: 716
33. Sandler AB, Cristou A, Fox S, Williams SD, Nichols CR, Turns M, Roth BJ (1998) A phase II trial of paclitaxel in refractory germ cell tumors. Cancer 82: 1381-1386